Second line lopinavir/ritonavir monotherapy was inferior to tenofovir/lamivudine/lopinavir/ritonavir in patients who failed NNRTI-regimen: HIV STAR study (original) (raw)

Warangkana Munsakul

2011, F1000posters

visibility

…

description

1 page

link

1 file

In patients who develop NNRTI-based treatment failure, genotypic-guided 2 NRTIs+ boosted protease inhibitor (bPI)-based HAART is recommended as the second-line therapy[1, 2]. In settings where viral load monitoring is not easily accessible and patients develop late virologic failure, it is not known whether recycling NRTIs plus a bPI is beneficial, compared to treating with bPI alone.